Drug intelligence / Profile preview

EB1010

Development stage: Preclinical
Lead developer: Enterome
Modality: Peptides
Administration: Oral

Overview

EB1010 is a preclinical, oral, microbiome-derived peptide drug candidate, specifically an IL-10 inducing agent (EndoMimic compound), developed by Enterome in collaboration with Nestlé Health Science. It is being investigated for the treatment of immune diseases, primarily food allergies (with an initial focus on peanut allergy) and inflammatory bowel disease (IBD). Clinical trials were anticipated to commence in either 2023 or 2024.

Targets

DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)IL10 (Interleukin-10)

Beyond the preview

Go deeper on EB1010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EB1010.